Policy & News
Heavyweight! mRNA vaccine combination therapy reduces melanoma death risk by 65%!
2023-06-06
On 5 June, mRNA vaccine giants Moderna and Merck Sharp & Dohme announced at the 2023 ASCO Annual Meeting that a Phase 2b study of the combination of the individualised oncology vaccine, mRNA-4157 (V940), and the anti-PD-1 therapy, Keytruda, demonstrated that the combination therapy, used in patients with surgically resected, high-risk melanoma (Stage III/IV), reduced the risk of spreading or dying from this skin cancer by 65%, compared to Keytruda alone.
View More
World's 2nd RSV vaccine approved for marketing by FDA
2023-06-05
On 31 May, Pfizer announced that its bivalent respiratory syncytial virus (RSV) vaccine, ABRYSVO (RSVpreF, PF-06928316), has been approved for marketing by the FDA for the prevention of lower respiratory tract disease (LRTD) caused by RSV in people 60 years of age and older, making it the second RSV vaccine approved for marketing in the world.
View More
World's first new plant-based crown vaccine approved in Canada
2023-01-09
Canada has become the first country in the world to authorise the use of a plant-based New Crown vaccine, ABC reports. On 24 February local time, Canadian regulators said they were allowing two doses of Medicago's New Crown vaccine to be administered to adults between the ages of 18 and 64, but said there was still too little data related to people aged 65 and older.
View More
Five Chinese drugmakers licensed to make generic versions of Pfizer's new Crown oral drug
2023-01-09
On 18 March Beijing time, the official website of Geneva Medicines PatentPool (MPP) announced that it had signed agreements with 35 companies, which were allowed to produce generic versions of nirmatrelvir, one of the components of Pfizer's new crown jewel, Paxlovid, as APIs or preparations.
View More
2023-01-09
Recently, two new inactivated coronavirus vaccines (Omicron variant, hereinafter referred to as "O-strain") developed by Sinopharm's China Biologicals Beijing Bioproducts Research Institute and Wuhan Bioproducts Research Institute have been approved by the Research Ethics Committee of the University of Hong Kong and Hong Kong Island West Hospital of the Hospital Authority, as well as by the Clinical Trial Approval from the Pharmacy and Poisons Board of Hong Kong, and have been formally authorised to carry out a sequential immunisation clinical study of the new coronavirus vaccines in Hong Kong.
View More
Sinopharm, Kexing Omicron variant of new crown vaccine approved for clinical use in China
2023-01-09
On 26 April, Sinopharm China Biotechnology Company Limited and Kexing Holdings Biotechnology Company Limited announced that their Omicron variant strain of inactivated neocoronavirus vaccine had been granted clinical approval by China's State Drug Administration respectively.
View More
